{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:15:31Z","timestamp":1792800931282,"version":"4.5.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Immune checkpoint inhibitor (ICI)-associated toxicities are uncommon but may rapidly progress to cardiogenic shock and death. Patients with thymoma are considered particularly vulnerable to severe immune-related adverse events because thymic malignancy is closely associated with impaired central immune tolerance and autoimmune dysregulation. We report a 34-year-old man with stage IV type B2 thymoma who developed initial myalgia and fatigue approximately 15 days after the most recent pembrolizumab-containing treatment cycle and progressed to fulminant ICI-associated myositis with respiratory failure and secondary cardiogenic shock by day 19. He presented with severe immune-mediated myositis, concurrent myocardial injury, left ventricular systolic dysfunction, cardiogenic shock, metabolic acidosis, acute kidney injury, acute liver injury, coagulopathy, and respiratory failure. Coronary angiography excluded obstructive coronary disease, and microbiological and virological investigations did not identify an infectious cause. Endomyocardial biopsy and cardiac magnetic resonance imaging were not feasible because of profound hemodynamic instability, VA-ECMO support, and coagulopathy. The patient was treated with early venoarterial extracorporeal membrane oxygenation (VA-ECMO), high-dose methylprednisolone, intravenous immunoglobulin, continuous renal replacement therapy, mechanical ventilation, and comprehensive organ support. Cardiac function improved from a left ventricular ejection fraction of 25% to 51%, VA-ECMO was discontinued on hospital day 7, and the patient survived to discharge. This case and a focused literature review suggest that thymoma-associated ICI myositis with secondary cardiac dysfunction may represent a high-risk phenotype characterized by early onset, overlap neuromuscular toxicity, severe hemodynamic compromise, and potential reversibility when early immunosuppression and advanced circulatory support are implemented.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1909262","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:33:43Z","timestamp":1789050823000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Fulminant immune checkpoint inhibitor-associated myositis presenting with concurrent myocardial injury and secondary cardiogenic shock in a patient with thymoma: a case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Min","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, the First Clinical Medical College of China Three Gorges University, Yichang Central People's Hospital","place":["Yichang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, the First Clinical Medical College of China Three Gorges University, Yichang Central People's Hospital","place":["Yichang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, the First Clinical Medical College of China Three Gorges University, Yichang Central People's Hospital","place":["Yichang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, the First Clinical Medical College of China Three Gorges University, Yichang Central People's Hospital","place":["Yichang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiru","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, the First Clinical Medical College of China Three Gorges University, Yichang Central People's Hospital","place":["Yichang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, the First Clinical Medical College of China Three Gorges University, Yichang Central People's Hospital","place":["Yichang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayuan","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, the First Clinical Medical College of China Three Gorges University, Yichang Central People's Hospital","place":["Yichang, China"]},{"name":"Department of Nursing, School of Health Sciences, China Three Gorges University","place":["Yichang, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e145186","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Investig"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review","volume":"14","author":"Lipe","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/cmi.2010.74","article-title":"Thymoma and autoimmunity","volume":"8","author":"Shelly","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"Journal Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/cancers14092060","article-title":"Immunotherapy for management of thymic epithelial tumors: a double-edged sword","volume":"14","author":"Ballman","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jcmg.2017.11.036","article-title":"Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors","volume":"11","author":"Ederhy","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"B12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"989431","DOI":"10.3389\/fphar.2022.989431","article-title":"The role of immune checkpoints in cardiovascular disease","volume":"13","author":"Yousif","year":"2022","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1340373","DOI":"10.3389\/fimmu.2024.1340373","article-title":"Immune checkpoint inhibitors associated cardiovascular immune-related adverse events","volume":"15","author":"Jo","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-l1: from cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1550400","DOI":"10.3389\/fimmu.2025.1550400","article-title":"ICI-induced cardiovascular toxicity: mechanisms and immune reprogramming therapeutic strategies","volume":"16","author":"Zheng","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jtho.2017.11.118","article-title":"Paraneoplastic syndromes and thymic malignancies: an examination of the international thymic malignancy interest group retrospective database","volume":"13","author":"Padda","year":"2018","journal-title":"J Thoracic Oncology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","article-title":"Pathophysiology and immunological profile of myasthenia gravis and its subgroups","volume":"49","author":"Romi","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","article-title":"Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review","volume":"135","author":"Konstantina","year":"2019","journal-title":"Lung Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1016\/j.cllc.2019.10.008","article-title":"Fatal simultaneous multi-organ failure following pembrolizumab treatment for refractory thymoma","volume":"21","author":"Hyun","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.21037\/cdt-21-147","article-title":"Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report","volume":"11","author":"Portol\u00e9s Hern\u00e1ndez","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"714460","DOI":"10.3389\/fcvm.2021.714460","article-title":"Case report: the neuromusclar triad of immune checkpoint inhibitors: a case report of myositis, myocarditis, and myasthenia gravis overlap following toripalimab treatment","volume":"8","author":"Luo","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"797009","DOI":"10.3389\/fcvm.2021.797009","article-title":"Sintilimab-induced myocarditis overlapping myositis in a patient with metastatic thymoma: a case report","volume":"8","author":"Yang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e01025","DOI":"10.1002\/rcr2.1025","article-title":"Early development of pembrolizumab-induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma","volume":"10","author":"Jang","year":"2022","journal-title":"Respirol Case Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted Abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e31873","DOI":"10.1097\/MD.0000000000031873","article-title":"Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: a case report","volume":"101","author":"Liu","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e33550","DOI":"10.1097\/MD.0000000000033550","article-title":"Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: a case report","volume":"102","author":"Wang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e70180","DOI":"10.1111\/1759-7714.70180","article-title":"Myocarditis and myasthenia gravis induced by camrelizumab in a patient with metastatic b2 thymoma: a case report","volume":"16","author":"Zhao","year":"2025","journal-title":"Thorac Cancer"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1909262\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:33:44Z","timestamp":1789050824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1909262\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":30,"alternative-id":["10.3389\/fcvm.2026.1909262"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1909262","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1909262"}}